RecruitingPhase 2

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

United States30 participantsStarted 2026-03-09

Plain-language summary

A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography) * Ability to provide written informed consent * Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner * Negative urine pregnancy test for anyone of childbearing potential at study entry Exclusion Criteria: * Pregnant women * Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers) * Prisoners * Hospitalizations (for any cause) within 2 weeks of study entry

What they're measuring

Recruitment and retention rates

Timeframe: up to 28 weeks

Incidence of Treatment-Emergent Adverse Events as assessed by participant report

Timeframe: up to 28 weeks

Pain assessed by the Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) Pain Impact questionnaire

Timeframe: up to 28 weeks

Trial details

NCT IDNCT06016634

SponsorUniversity of California, Davis

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

Contact for this trial

Leyla Y Teos, PhD

(916) 460-2749 lyteos@ucdavis.edu

View on ClinicalTrials.gov More Sickle Cell Disease trials